RecruitingPHASE1, PHASE2NCT05133882

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sunshine Lake Pharma Co., Ltd.
Principal Investigator
Jie Jin, Doctor
First Affiliated Hospital of Zhejiang University
Intervention
Clifutinib Besylate(drug)
Enrollment
133 enrolled
Eligibility
18 years · All sexes
Timeline
20222026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05133882 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease

← Back to all trials